Loading
A phase 1/2 trial of Linvoseltamab in multiple myeloma, run by Regeneron Pharmaceuticals, now recruiting.
A Study to Assess the Safety and Anti-Tumor Activity of REGN7945 in Combination With Linvoseltamab in Adult Participants With Relapsed/Refractory Multiple Myeloma is a phase 1/2 interventional study registered as NCT06669247 by Regeneron Pharmaceuticals, with 186 participants planned, started 2024-12-11 and due to reach its primary completion in 2033-11-11. Interventions recorded: Linvoseltamab, REGN7945+Linvoseltamab. Conditions listed: Relapsed/Refractory Multiple Myeloma. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Linvoseltamab, Regeneron, Relapsed or refractory multiple myeloma, T-cell engagers (bispecific).
Shares Linvoseltamab, Regeneron, T-cell engagers (bispecific), Multiple myeloma.
Shares Linvoseltamab, Regeneron, Relapsed or refractory multiple myeloma, T-cell engagers (bispecific).
Shares Linvoseltamab, Regeneron, T-cell engagers (bispecific), Multiple myeloma.
Shares Linvoseltamab, Regeneron, T-cell engagers (bispecific), Multiple myeloma.
Shares Linvoseltamab, Regeneron, T-cell engagers (bispecific), Multiple myeloma.
Shares Linvoseltamab, Regeneron, Relapsed or refractory multiple myeloma, T-cell engagers (bispecific).
Shares Relapsed or refractory multiple myeloma, T-cell engagers (bispecific), Multiple myeloma.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/